ライフサイエンスコーパス: selective serotonin reuptake inhibitor

1 Nav1.5 blocking properties of fluoxetine, a selective serotonin reuptake inhibitor.

2 lerance or lack of remission with an initial selective serotonin reuptake inhibitor.

3 lesions; both behaviours are alleviated by a selective serotonin reuptake inhibitor.

4 owing would be unresponsive to fluoxetine, a selective serotonin reuptake inhibitor.

5 serotonin in rat frontal cortex typical of a selective serotonin reuptake inhibitor.

6 al hippocampus following administration of a selective serotonin reuptake inhibitor.

7 CK1) inhibitor, the other from paroxetine, a selective serotonin-reuptake inhibitor.

8 hotics to Depressive patients medicated with Selective Serotonin Reuptake Inhibitors.

9 hypersensitivity, and response to long-term selective serotonin reuptake inhibitors.

10 ve add-on in patients that do not respond to selective serotonin reuptake inhibitors.

11 tment in the absence of prenatal exposure to selective serotonin reuptake inhibitors.

12 more sensitive to SERT inhibitors, including selective serotonin reuptake inhibitors.

13 ic dementia, often respond to treatment with selective serotonin reuptake inhibitors.

14 ries the same FDA "black box" warning as the selective serotonin reuptake inhibitors.

15 ples; and pharmacological treatments, mainly selective serotonin reuptake inhibitors.

16 ffects beyond 12 weeks outside of those with selective serotonin reuptake inhibitors.

17 .90), compared with patients who did not use selective serotonin reuptake inhibitors.

18 (S allele) results in decreased efficacy of selective serotonin reuptake inhibitors.

19 s and appears to lack drug interactions with selective serotonin reuptake inhibitors.

20 d in mediating the antidepressant actions of selective serotonin reuptake inhibitors.

21 Selective serotonin reuptake inhibitors accounted for 80

22 I was significantly lower in patients taking selective serotonin reuptake inhibitors (adjusted hazard

23 In contrast, the use of selective serotonin reuptake inhibitors (aHR for MOF, 1.

24 Clinical trial data support selective serotonin reuptake inhibitors and amantadine t

25 summarizes recent developments in the use of selective serotonin reuptake inhibitors and atypical ant

26 The principal treatments are selective serotonin reuptake inhibitors and behavioural

27 onin transporter (5-HTT) is a key target for selective serotonin reuptake inhibitors and may be invol

28 onflicting evidence and guidelines regarding selective serotonin reuptake inhibitors and suicidality

29 Other tremorogenic drugs, such as selective serotonin reuptake inhibitors and tricyclic an

30 5), benzodiazepines (-0.96, -1.56 to -0.36), selective serotonin-reuptake inhibitors and serotonin-no

31 and pharmacological treatments, particularly selective serotonin-reuptake inhibitors and serotonin-no

32 nin in healthy volunteers with citalopram (a selective serotonin reuptake inhibitor) and contrasted i

33 s fluids, benzodiazapines, and withdrawal of selective serotonin-reuptake inhibitor) and received cyp

34 e transgenerational effects of sertraline, a selective serotonin reuptake inhibitor, and venlafaxine,

35 ective, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and a new agent

36 drugs, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and norepinephr

37 ents, such as atypical antipsychotic agents, selective serotonin reuptake inhibitors, and selective s

38 treatment-related issues: suicide risk with selective serotonin reuptake inhibitors, and the safety

39 We use this line to demonstrate that the selective serotonin reuptake inhibitor antidepressant fl

40 deficits and that the neurogenic effects of selective serotonin reuptake inhibitor antidepressants c

41 For patients taking non-selective serotonin reuptake inhibitor antidepressants,

42 , but not acute, treatment with tricyclic or selective serotonin reuptake inhibitor antidepressants.

43 of fluoxetine, and thus it remains the only selective serotonin reuptake inhibitor approved by the U

44 Selective serotonin reuptake inhibitors are the most wid

45 Selective serotonin reuptake inhibitors are widely presc

46 Current treatments, such as selective serotonin reuptake inhibitors, are not ideal b

47 Compared with selective serotonin reuptake inhibitors as a drug class,

48 ent evidence continues to support the use of selective serotonin reuptake inhibitors as first-line ph

49 anwhile, evidence supporting the efficacy of selective serotonin reuptake inhibitors, augmentation st

50 a slight shift in prescribing toward the non-selective serotonin reuptake inhibitor bupropion hydroch

51 d risk of ASD associated with treatment with selective serotonin reuptake inhibitors by the mother du

52 ed the 10-year risk of MOF by 36% for use of selective serotonin reuptake inhibitors, by 63% for use

53 -year risk of hip fracture by 57% for use of selective serotonin reuptake inhibitors, by 98% for use

54 ized in a double-blind design to receive the selective serotonin reuptake inhibitor citalopram (20 mg

55 We therefore examined whether the selective serotonin reuptake inhibitor citalopram improv

56 The selective serotonin reuptake inhibitor citalopram reduce

57 A subset of animals received selective serotonin reuptake inhibitor citalopram starti

58 Open-label trials with the selective serotonin reuptake inhibitor citalopram sugges

59 ogical antagonists (BI-11A7 and BI-2A7); the selective serotonin reuptake inhibitor citalopram was us

60 mobility activity of a subactive dose of the selective serotonin reuptake inhibitor citalopram.

61 ological challenge with an acute dose of the selective serotonin reuptake inhibitor, citalopram, reve

62 e, on the cerebral metabolic response to the selective serotonin reuptake inhibitor, citalopram.

63 seline and in response to challenge with the selective serotonin reuptake inhibitor, citalopram.

64 xamined whether fluoxetine, the prototypical selective serotonin reuptake inhibitor, differentially m

65 her genetic deletion or brief treatment with selective serotonin reuptake inhibitors during developme

66 Use of selective serotonin reuptake inhibitors during the secon

67 m effects of exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, during adolescen

68 Use of antidepressants, specifically selective serotonin reuptake inhibitors, during the seco

69 rimary target for antidepressants, including selective serotonin reuptake inhibitors (e.g. (S)-citalo

70 f estrogen without its deleterious effect on selective serotonin reuptake inhibitor efficacy.

71 ed during 8 weeks with either placebo or the selective serotonin reuptake inhibitor escitalopram.

72 ssociated with subsequent remission with the selective serotonin reuptake inhibitor escitalopram; thi

73 allele responded significantly better to the selective serotonin reuptake inhibitors escitalopram and

74 tment and 8 weeks after randomization to the selective serotonin reuptake inhibitors escitalopram and

75 tigated whether a 3-week administration of a selective serotonin reuptake inhibitor, expected to incr

76 Treatment with the selective serotonin reuptake inhibitor fluoxetine suppre

77 ramine, instead mirrored the behavior of the selective serotonin reuptake inhibitor fluoxetine, both

78 Postnatal treatment with the selective serotonin reuptake inhibitor fluoxetine, evoke

79 were also reversed by administration of the selective serotonin reuptake inhibitor fluoxetine.

80 ety-like behaviors, and is alleviated by the selective serotonin reuptake inhibitor fluoxetine.

81 -HT transport and binding of cocaine and the selective serotonin reuptake inhibitors fluoxetine and e

82 inhibits the antidepressant efficacy of the selective-serotonin reuptake inhibitor fluoxetine (FLX)

83 threo-dihydroxyphenylserine at 5 mg/kg) or a selective serotonin reuptake inhibitor (fluoxetine at 20

84 e individually exposed to acute doses of the selective serotonin reuptake inhibitor, fluoxetine (5 or

85 s with classical therapeutics, including the selective serotonin reuptake inhibitor, fluoxetine.

86 l or progesterone blocked the ability of the selective serotonin reuptake inhibitor, fluvoxamine, to

87 d trials began demonstrating the efficacy of selective serotonin reuptake inhibitors for these condit

88 ial direct-current stimulation (tDCS) with a selective serotonin-reuptake inhibitor for the treatment

89 matized IF-CCKR-2 tg mice with fluoxetine, a selective serotonin reuptake inhibitor, for a period of

90 Fluoxetine, a selective serotonin reuptake inhibitor, has been found r

91 Fluoxetine, a selective serotonin reuptake inhibitor, has been reporte

92 Fluoxetine (FLX), a selective serotonin reuptake inhibitor, has similar effe

93 Although cognitive behavioral therapy and selective serotonin-reuptake inhibitors have shown effic

94 cerebral cortex are powerfully modulated by selective serotonin reuptake inhibitors, however, direct

95 SADHART) tested the safety and efficacy of a selective serotonin reuptake inhibitor in this populatio

96 ajor randomized placebo-controlled trials of selective serotonin reuptake inhibitors in adolescents h

97 Use of selective serotonin reuptake inhibitors in depressed pat

98 sk estimates for each drug individually, for selective serotonin reuptake inhibitors in depression tr

99 The overall risk ratio for selective serotonin reuptake inhibitors in depression tr

100 Although the acute effect of selective serotonin reuptake inhibitors in elevating syn

101 ts, and could be relevant to some actions of selective serotonin reuptake inhibitors in humans.

102 ctively over a 12-week treatment course with selective serotonin reuptake inhibitors in late-life dep

103 the use of cognitive behavioral therapy and selective serotonin reuptake inhibitors in the treatment

104 Long-term efficacy and safety of selective serotonin reuptake inhibitors in these patient

105 The efficacy and adverse events of selective serotonin reuptake inhibitors in these patient

106 the number of children exposed prenatally to selective serotonin reuptake inhibitors in this populati

107 We identified citalopram, a selective serotonin reuptake inhibitor, in a small molec

108 take and biological effects of fluoxetine, a selective serotonin reuptake inhibitor, in filter and de

109 profile of using antidepressants, especially selective serotonin reuptake inhibitors, in depressed ch

110 outcomes, but antidepressant treatment with selective serotonin reuptake inhibitors is generally saf

111 pressant paroxetine (Paxil), the most potent selective serotonin reuptake inhibitor known.

112 Selective serotonin reuptake inhibitors may provide bene

113 Although selective serotonin reuptake inhibitors may reduce morta

114 d MDDs (untreated, n = 12), MDD treated with selective serotonin reuptake inhibitors (MDD*SSRI, n = 6

115 trials of second-generation antidepressants (selective serotonin reuptake inhibitors, nefazodone, ven

116 Use of selective serotonin reuptake inhibitors, nonbenzodiazepi

117 with depression classified as responsive to selective serotonin reuptake inhibitors (odds ratio=1.55

118 estigations into the effects of OLZ, but not selective serotonin reuptake inhibitors, on core feature

119 o ongoing antidepressant medication therapy (selective serotonin reuptake inhibitor or serotonin and

120 health and physical health, treatment with a selective serotonin reuptake inhibitor or serotonin-nore

121 nd were randomized to receive either another selective serotonin reuptake inhibitor or venlafaxine, w

122 wed by a 10-week open-label treatment with a selective serotonin reuptake inhibitor or, in some cases

123 xib, ondansetron) either in combination with selective serotonin reuptake inhibitors or as monotherap

124 rol in the treatment of depression by use of selective serotonin reuptake inhibitors or psychological

125 macologically untreated maternal depression, selective serotonin reuptake inhibitors or serotonin and

126 ctively downregulated by the acute action of selective serotonin reuptake inhibitors or serotonin at

127 dence interval [CI] = 1.10-15.14) and use of selective serotonin reuptake inhibitors (OR = 2.66; 95%

128 er, this includes tricyclic antidepressants, selective serotonin reuptake inhibitors, or psychosocial

129 The selective serotonin reuptake inhibitor, paroxetine, was

130 Fluoxetine is the only selective serotonin reuptake inhibitor registered for th

131 cognitive behavioral therapy with or without selective serotonin reuptake inhibitors remains a prefer

132 Whether this model is responsive to selective serotonin reuptake inhibitors remains unspecif

133 ticularly in women with MDD or anxiety, with selective serotonin reuptake inhibitors reported as the

134 effects of classic antidepressants, such as selective serotonin reuptake inhibitors, require a month

135 tion, acute itch triggered by serotonin or a selective serotonin reuptake inhibitor required both HTR

136 r adolescent exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, results in chang

137 Only one case report suggested benefit from selective serotonin reuptake inhibitor/serotonin-norepin

138 re may be excess morbidity in critically ill selective serotonin reuptake inhibitor/serotonin-norepin

139 Selective serotonin reuptake inhibitor/serotonin-norepin

140 ed for studies of ICU patients with recorded selective serotonin reuptake inhibitor/serotonin-norepin

141 ting, it was generally unclear if outpatient selective serotonin reuptake inhibitor/serotonin-norepin

142 istics in exposed and control groups; use of selective serotonin reuptake inhibitor/serotonin-norepin

143 needed to help clinicians decide when to use selective serotonin reuptake inhibitor/serotonin-norepin

144 8 weeks of antidepressant treatment with the selective serotonin reuptake inhibitor sertraline hydroc

145 Chronic selective serotonin reuptake inhibitor (SSRI) administra

146 als have indicated that the combination of a selective serotonin reuptake inhibitor (SSRI) and a stat

147 e disorder, either untreated or treated with selective serotonin reuptake inhibitor (SSRI) antidepres

148 antidepressant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepres

149 DA, and displays distinct sensitivity to the selective serotonin reuptake inhibitor (SSRI) antidepres

150 d by 25% following administration of several selective serotonin reuptake inhibitor (SSRI) antidepres

151 cal antipsychotic medications; fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepres

152 Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepres

153 The association between selective serotonin reuptake inhibitor (SSRI) antidepres

154 Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram

155 This study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram

156 ing Caucasian subjects were administered the selective serotonin reuptake inhibitor (SSRI) citalopram

157 lacked the early anxiogenic response to the selective serotonin reuptake inhibitor (SSRI) fluoxetine

158 acy in rats and advantages compared with the selective serotonin reuptake inhibitor (SSRI) fluoxetine

159 depressant (TCA) desipramine (10 mg/kg), the selective serotonin reuptake inhibitor (SSRI) fluoxetine

160 pothesis that 6 weeks' administration of the selective serotonin reuptake inhibitor (SSRI) fluoxetine

161 The selective serotonin reuptake inhibitor (SSRI) fluoxetine

162 study revealed that chronic treatment with a selective serotonin reuptake inhibitor (SSRI) impairs th

163 A subset of patients started on a selective serotonin reuptake inhibitor (SSRI) initially

164 an empirically supported psychotherapy with selective serotonin reuptake inhibitor (SSRI) pharmacoth

165 le-blind, randomized controlled trial of the selective serotonin reuptake inhibitor (SSRI) sertraline

166 Prior to beginning treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline

167 e disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy.

168 compounds was synthesized by linking a novel selective serotonin reuptake inhibitor (SSRI) to a PDE4

169 Although selective serotonin reuptake inhibitor (SSRI) treatment

170 s examined the relationship between prenatal selective serotonin reuptake inhibitor (SSRI) treatment

171 Selective serotonin reuptake inhibitor (SSRI) use during

172 porter (hSERT) were synthesized based on the selective serotonin reuptake inhibitor (SSRI), (S)-cital

173 Effects of duloxetine hydrochloride, selective serotonin reuptake inhibitor (SSRI), and covar

174 Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), blocks GC

175 postnatal days 8-21) exposure of rats to the selective serotonin reuptake inhibitor (SSRI), citalopra

176 In the presence of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), concentra

177 ors that are not rescued with the prototypic selective serotonin reuptake inhibitor (SSRI), fluoxetin

178 investigated the effects of escitalopram, a selective serotonin reuptake inhibitor (SSRI), on brain

179 -up analyses demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), provided

180 Adolescents (ages 12-18 years) with selective serotonin reuptake inhibitor (SSRI)-resistant

181 ic treatment with citalopram, a prototypical selective serotonin reuptake inhibitor (SSRI).

182 ients and after 8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI).

183 esponse to an initial treatment trial with a selective serotonin reuptake inhibitor (SSRI).

184 ients and after ~8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI).

185 Here, we show that when the effects of a selective serotonin reuptake inhibitor (SSRI, citalopram

186 Selective serotonin reuptake inhibitors (SSRI's) enhance

187 Selective serotonin reuptake inhibitors (SSRI) are aimed

188 Selective serotonin reuptake inhibitors (SSRI) are known

189 ve demonstrated that acute administration of selective serotonin reuptake inhibitors (SSRI) can affec

190 ible association between maternal use of the selective serotonin-reuptake inhibitor (SSRI) fluoxetine

191 unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not

192 ar mechanisms explaining hormetic effects of selective serotonin reuptake inhibitors (SSRIs) and 4-no

193 seems to be a correlation between the use of selective serotonin reuptake inhibitors (SSRIs) and a de

194 The strongest evidence supports use of selective serotonin reuptake inhibitors (SSRIs) and cogn

195 olescents in randomized controlled trials to selective serotonin reuptake inhibitors (SSRIs) and cons

196 lasses of antidepressants, prescriptions for selective serotonin reuptake inhibitors (SSRIs) and othe

197 ike behaviors, both of which are reversed by selective serotonin reuptake inhibitors (SSRIs) and the

198 Selective serotonin reuptake inhibitors (SSRIs) are a fi

199 Selective serotonin reuptake inhibitors (SSRIs) are anti

200 Compared with placebo, selective serotonin reuptake inhibitors (SSRIs) are asso

201 Selective Serotonin Reuptake Inhibitors (SSRIs) are comm

202 Selective serotonin reuptake inhibitors (SSRIs) are comm

203 Selective serotonin reuptake inhibitors (SSRIs) are comm

204 Selective serotonin reuptake inhibitors (SSRIs) are effi

205 Selective serotonin reuptake inhibitors (SSRIs) are freq

206 Selective serotonin reuptake inhibitors (SSRIs) are ofte

207 Selective serotonin reuptake inhibitors (SSRIs) are ofte

208 Selective serotonin reuptake inhibitors (SSRIs) are the

209 Selective serotonin reuptake inhibitors (SSRIs) are the

210 Selective serotonin reuptake inhibitors (SSRIs) are wide

211 Selective serotonin reuptake inhibitors (SSRIs) are wide

212 Selective serotonin reuptake inhibitors (SSRIs) are wide

213 Selective serotonin reuptake inhibitors (SSRIs) are wide

214 Although selective serotonin reuptake inhibitors (SSRIs) are wide

215 Are selective serotonin reuptake inhibitors (SSRIs) associat

216 Selective serotonin reuptake inhibitors (SSRIs) display

217 Use of selective serotonin reuptake inhibitors (SSRIs) during p

218 cern about an association between the use of selective serotonin reuptake inhibitors (SSRIs) during p

219 It is unknown whether exposure to selective serotonin reuptake inhibitors (SSRIs) during p

220 e has been ongoing controversy as to whether selective serotonin reuptake inhibitors (SSRIs) exhibit

221 of suicidality in pediatric patients taking selective serotonin reuptake inhibitors (SSRIs) for depr

222 of suicidality in pediatric patients taking selective serotonin reuptake inhibitors (SSRIs) for depr

223 .S. and Dutch data on prescription rates for selective serotonin reuptake inhibitors (SSRIs) from 200

224 Use of selective serotonin reuptake inhibitors (SSRIs) has been

225 Chronic treatments with selective serotonin reuptake inhibitors (SSRIs) have bee

226 In both rats and men, selective serotonin reuptake inhibitors (SSRIs) impair e

227 The safety and efficacy of selective serotonin reuptake inhibitors (SSRIs) in adole

228 xamined modulation of synaptic plasticity by selective serotonin reuptake inhibitors (SSRIs) in hippo

229 ies suggested that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major

230 r (nAChR) blockers potentiate the effects of selective serotonin reuptake inhibitors (SSRIs) in some

231 sion and attention, and the effectiveness of selective serotonin reuptake inhibitors (SSRIs) in treat

232 rs investigated whether in utero exposure to selective serotonin reuptake inhibitors (SSRIs) increase

233 Elevating serotonin (5-HT) levels with selective serotonin reuptake inhibitors (SSRIs) is the m

234 Selective serotonin reuptake inhibitors (SSRIs) may incr

235 d, treating animals with MAO-A inhibitors or selective serotonin reuptake inhibitors (SSRIs) normaliz

236 was to assess the effects of treatment with selective serotonin reuptake inhibitors (SSRIs) on the r

237 placebo in meta-analyses of 7 comparisons of selective serotonin reuptake inhibitors (SSRIs) or serot

238 dicines (CSM) advised against treatment with selective serotonin reuptake inhibitors (SSRIs) other th

239 Selective serotonin reuptake inhibitors (SSRIs) represen

240 Compared with pill placebo, selective serotonin reuptake inhibitors (SSRIs) signific

241 ted with PD, and clinical data indicate that selective serotonin reuptake inhibitors (SSRIs) such as

242 and its eutomer, escitalopram (S-(+)-1) are selective serotonin reuptake inhibitors (SSRIs) that are

243 s risk from concomitant use of nsNSAIDs with selective serotonin reuptake inhibitors (SSRIs) was 1.6,

244 Selective serotonin reuptake inhibitors (SSRIs) were int

245 recent studies linking in utero exposure to selective serotonin reuptake inhibitors (SSRIs) with per

246 erotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and mat

247 n between use of antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), and sui

248 ion do not respond to initial treatment with selective serotonin reuptake inhibitors (SSRIs), and thi

249 ear how perinatal exposure to drugs, such as selective serotonin reuptake inhibitors (SSRIs), impacts

250 Selective serotonin reuptake inhibitors (SSRIs), in addi

251 rapy were compared for patients who received selective serotonin reuptake inhibitors (SSRIs), new-gen

252 broad range of therapeutic agents including selective serotonin reuptake inhibitors (SSRIs), seroton

253 t of several antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), seroton

254 examine the relative efficacy and safety of selective serotonin reuptake inhibitors (SSRIs), seroton

255 Selective serotonin reuptake inhibitors (SSRIs), such as

256 lizers, which dampen limbic irritability, or selective serotonin reuptake inhibitors (SSRIs), which m

257 nteraction of fluoxetine and paroxetine, two selective serotonin reuptake inhibitors (SSRIs), with th

258 or Depressive Disorder who are treated with Selective Serotonin Reuptake Inhibitors (SSRIs).

259 red for behavioral and cellular responses to selective serotonin reuptake inhibitors (SSRIs).

260 who had a partial response or no response to selective serotonin reuptake inhibitors (SSRIs).

261 isk of preeclampsia among women treated with selective serotonin reuptake inhibitors (SSRIs).

262 both biochemical and behavioral responses to selective serotonin reuptake inhibitors (SSRIs).

263 during cognitive-behavioral therapy (CBT) or selective serotonin reuptake inhibitors (SSRIs).

264 an important role in modulating response to selective serotonin reuptake inhibitors (SSRIs).

265 tonin in vitro and functionally responded to selective serotonin reuptake inhibitors (SSRIs).

266 been observed in patients chronically taking selective serotonin reuptake inhibitors (SSRIs).

267 ersive behaviour following acute exposure to selective serotonin reuptake inhibitors (SSRIs).

268 roidal anti-inflammatory drugs (NSAIDs), and selective serotonin reuptake inhibitors (SSRIs).

269 iated with the introduction and diffusion of selective serotonin reuptake inhibitors (SSRIs).

270 the population and is commonly treated with selective serotonin reuptake inhibitors (SSRIs; e.g., Pr

271 Whether the use of selective serotonin-reuptake inhibitors (SSRIs) and othe

272 HMG-CoA) reductase inhibitors (statins), and selective serotonin-reuptake inhibitors (SSRIs) and sero

273 The use of selective serotonin-reuptake inhibitors (SSRIs) has been

274 of birth defects after antenatal exposure to selective serotonin-reuptake inhibitors (SSRIs) remains

275 (DR) attenuates the therapeutic activity of selective serotonin-reuptake inhibitors (SSRIs), whereas

276 Antidepressant use (selective serotonin reuptake inhibitors [SSRIs] or serot

277 ed duloxetine to comparators (venlafaxine or selective serotonin reuptake inhibitors [SSRIs], and ind

278 s, calcium channel blockers, loop diuretics, selective serotonin reuptake inhibitors, statins, and th

279 unintended declines in case finding and non-selective serotonin reuptake inhibitor substitute treatm

280 Selective serotonin reuptake inhibitors, such as fluoxet

281 urtailed with subchronic administration of a selective serotonin reuptake inhibitor, suggesting the p

282 As in major depression, selective serotonin reuptake inhibitors targeting brain

283 participants who required the addition of a selective serotonin reuptake inhibitor to achieve remiss

284 Sertraline is the first selective serotonin reuptake inhibitor to demonstrate a

285 Behavioral changes were rescued by acute selective serotonin reuptake inhibitor treatment, suppor

286 ses were used to assess cataract surgery and selective serotonin reuptake inhibitor treatment.

287 ve bias develops in patients with MDD during selective serotonin reuptake inhibitor treatment.

288 , anhedonia, and an increased sensitivity to selective serotonin reuptake inhibitor treatment.

289 Acute SSRI (selective serotonin reuptake inhibitor) treatment has be

290 nonbenzodiazepine hypnotics, beta-blockers, selective serotonin reuptake inhibitors, tricyclic antid

291 according to whether patients were receiving selective serotonin reuptake inhibitors, tricyclic antid

292 ed to compute odds ratios for differences in selective serotonin reuptake inhibitor use between cases

293 Selective serotonin reuptake inhibitor use decreased in

294 Selective serotonin reuptake inhibitor use of 1 or more

295 Selective serotonin reuptake inhibitor use of 1 or more

296 the potential for pediatric suicidality with selective serotonin reuptake inhibitor use.

297 higher New York Heart Association class, and selective serotonin reuptake inhibitor use.

298 ry cohort of 6024 residents, 1024 (17%) were selective serotonin reuptake inhibitor users compared to

299 For SERT analysis, patients on selective serotonin reuptake inhibitor were excluded (n

300 articipants who were partial responders to a selective serotonin reuptake inhibitor were randomized t